# Omalizumab to Treat Eosinophilic Gastroenteritis

> **NCT00084097** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 30 (—)

## Conditions studied

- Gastroenteritis

## Interventions

- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT00084097
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06-02
- **Primary completion:** —
- **Final completion:** 2007-02-05
- **Target enrollment:** 30 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084097, "Omalizumab to Treat Eosinophilic Gastroenteritis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00084097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*